British Biotech PLC
Division of Ligand Pharmaceuticals Inc.
Latest From British Biotech PLC
The chairman of Sofinnova Partners told Scrip his newly launched biotech start-up fund aims to profit from Europe’s top science, relatively realistic asset prices, and geopolitical position between the US and China.
The medical device industry is full of companies that started out focusing on one therapeutic area only to shift gears and apply their original or another technooloogy to a different clinical need. Indeed, Biocompatibles is now workiing on its third primary therapeutic areas--cancer--having previously sold off its first two businesses, in ophthalmology and then, convinced it was too far behind in drug-eluting stents, cardiovascular. This new growth area is being driven by the company's general expertise in polymer technology and drug delivery.
Conforma Therapeutics' recent research finding may well inspire other companies to combine the best of traditional and new drug discovery methods: the start-up identified an old, natural compound by its physiological properties, then through modern technologies deduced the reason that it works.
Consolidation among Europe's biotech firms is picking up, but less for strategic reasons than simply to secure the cash to survive. Whatever the drivers, though, and however ruthless the concurrent cost- and program cutting, M&A should help create better adapted, bigger companies-something investors have long been calling for. Indeed for most merging companies, M&A is just the first step towards more strategic business-building moves in the near future.
- Therapeutic Areas
- British Biotech Pharmaceuticals Ltd.
- Western Europe
- Parent & Subsidiaries
- Ligand Pharmaceuticals Inc.
- Senior Management
Tony Weir, Dir., Fin.
Peter Fellner, Chmn.
- Contact Info
British Biotech PLC
Phone: (44) 118 977 3133
Oakdene Ct. 613 Reading Rd..
Wokingham, RG41 5UA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.